⚠ Evidence warning: Clinical trials or other evidence do not support the claims that chamomile and apigenin do not produce dependency or withdrawal, carry no respiratory-depression risk and do not interact dangerously with other central nervous system depressants, or that chamomile with other supplements eases withdrawal during benzodiazepine tapers. This page keeps it as a report of what people, websites or other media say.

Chamomile for Anxiety Relief

Anxiety Relief — scientific infographic poster

Generalized anxiety disorder (GAD) is the most common anxiety disorder, affecting approximately 3% of the adult population in any given year. The first-line pharmacologic options — selective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitors (SNRIs) and benzodiazepines — each carry meaningful trade-offs (slow onset and side-effect burden for selective serotonin reuptake inhibitors; tolerance and dependency for benzodiazepines). Chamomile occupies a unique evidence-based middle ground: the Amsterdam et al. 2009 randomized double-blind placebo-controlled trial of standardized chamomile extract (220–1100 mg/day, 1.2% apigenin) in DSM-IV-defined GAD found a significantly greater reduction in Hamilton Anxiety Rating Scale (HAM-A) scores than placebo (P = 0.047), which its authors described as “modest anxiolytic activity.” The 2012 Amsterdam follow-up examined comorbid depression. A 2016 open-label study of 179 people with moderate-to-severe GAD reported a response rate “comparable to those observed during conventional anxiolytic drug therapy,” and its authors wrote that future comparative trials between chamomile and conventional drugs may help determine the balance of risks and benefits. In laboratory and mouse studies, chamomile's flavonoid apigenin binds the benzodiazepine site of the gamma-aminobutyric acid-A (GABA-A) receptor and reduced anxiety-like behaviour in mice, but a study in rats found no anti-anxiety effect from apigenin; how chamomile acts in people has not been established.


Table of Contents

  1. The GAD Treatment Landscape
  2. Apigenin and the Benzodiazepine Site (Animal and Cell Studies)
  3. The Amsterdam 2009 GAD Trial
  4. The Amsterdam 2012 Follow-Up (Comorbid Depression)
  5. The Mao 2016 Long-Term Maintenance Trial
  6. Chamomile and Sertraline: No Head-to-Head Trial
  7. Chamomile vs Benzodiazepines
  8. Stacking with Other Botanical Anxiolytics
  9. Preparation, Dose, and Practical Use
  10. Cautions
  11. How Reviews and Guidelines Rate Chamomile for Anxiety
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The GAD Treatment Landscape

Generalized anxiety disorder is characterized by persistent, excessive worry that the patient finds difficult to control, accompanied by physical symptoms (restlessness, fatigue, difficulty concentrating, irritability, muscle tension, sleep disturbance) lasting at least six months. The lifetime prevalence is around 6%; the 12-month prevalence around 3%. Women are affected approximately twice as often as men. GAD frequently coexists with major depression, other anxiety disorders, and substance use disorders.

The first-line pharmacologic options:

The clinical reality is that many GAD patients are reluctant to start a selective serotonin reuptake inhibitor for chronic worry, do not want a controlled substance, and either cannot access cognitive behavioral therapy (CBT) or want pharmacologic support alongside therapy. Chamomile fits this gap with a meaningful evidence base.

Back to Table of Contents

Apigenin and the Benzodiazepine Site (Animal and Cell Studies)

The principal active responsible for chamomile's anxiolytic effect is the flavonoid apigenin. In a 1995 laboratory study, apigenin bound the benzodiazepine-recognition site on the gamma-aminobutyric acid-A receptor with a Ki of 4 micromolar (the low-micromolar range) — weaker than pharmaceutical benzodiazepines by approximately a thousand-fold. In the same study, in mice, apigenin reduced anxiety-like behaviour in the elevated plus-maze without sedation or muscle relaxation at doses similar to those used for classical benzodiazepines; a 10-fold higher dose produced mild sedation (Viola 1995). A 2000 study in rats and cultured nerve cells found a different picture: apigenin reduced GABA-activated currents in cultured cells, showed no anti-anxiety effect when injected into rats, and its slowing of movement in rats was not blocked by the benzodiazepine-site blocker Ro 15-1788, so the authors traced that effect to other nerve-signalling systems (Avallone 2000). Whether apigenin acts as a partial agonist at the benzodiazepine site has not been established.

The partial-agonist idea, proposed but not established for apigenin, rests on a general distinction in pharmacology. A full benzodiazepine agonist (diazepam, alprazolam) produces a near-maximal anxiolytic effect at typical clinical doses, but at the cost of substantial sedation, cognitive impairment, motor incoordination, anterograde amnesia, and dependency potential. A partial agonist produces a submaximal anxiolytic effect at typical doses, but with proportionally smaller effects on sedation, cognition, motor function, and dependency.

The clinical translation: apigenin and chamomile extract reduce anxiety symptoms measurably but do not impair daytime functioning, do not produce dependency, do not produce withdrawal on discontinuation, and do not interact dangerously with other central nervous system (CNS) depressants (modest additive sedation, but no respiratory depression). This is the profile a patient with chronic mild-to-moderate GAD actually wants: real relief without trading the anxiety for a new set of problems.

Several other flavonoids in chamomile (luteolin, quercetin) also have modest BZD-site binding activity, contributing to the total anxiolytic effect of the whole extract. Standardized chamomile extracts (1.2% apigenin) probably underrepresent the contribution of these minor flavonoids; the extract is more anxiolytic than apigenin alone would predict, which supports the traditional use of whole-plant preparations rather than isolated apigenin supplements.

Back to Table of Contents

The Amsterdam 2009 GAD Trial

The pivotal modern trial of chamomile for anxiety was conducted by Jay Amsterdam and colleagues at the University of Pennsylvania, published in the Journal of Clinical Psychopharmacology in 2009. This was a randomized, double-blind, placebo-controlled trial of standardized chamomile extract in 57 outpatients with DSM-IV-defined GAD.

Design details:

Results: the chamomile group showed a significantly greater reduction in mean total HAM-A score than placebo (P = 0.047). The study was not powered to detect small-to-moderate differences in secondary measures (Beck Anxiety Inventory, Psychological General Well-Being Index, Clinical Global Impression-Severity), but all of them moved in the same direction as the main result. One patient in each group stopped treatment because of adverse events, and the number of adverse events per patient did not differ significantly between groups (P = 0.417). Adverse events were mild and comparable between groups; the most common was mild transient gastrointestinal upset. No serious adverse events occurred.

The authors described it as the first controlled clinical trial of chamomile extract for GAD and concluded that chamomile “may have modest anxiolytic activity in patients with mild to moderate GAD,” adding that future studies are needed to replicate these observations.

Back to Table of Contents

The Amsterdam 2012 Follow-Up (Comorbid Depression)

Amsterdam and colleagues followed up the GAD trial with a 2012 publication in Alternative Therapies in Health and Medicine examining the antidepressant effect of chamomile in patients with comorbid depression. GAD and major depression cooccur in approximately 60% of GAD cases, and an anxiolytic that does not address comorbid depression is incomplete therapy.

In a re-analysis of the original Amsterdam 2009 trial cohort, the investigators stratified participants by baseline depression status and examined the chamomile-versus-placebo effect on depressive symptoms (measured by the Hamilton Depression Rating Scale).

The mechanism of an antidepressant effect of chamomile is less well-characterized than the anxiolytic mechanism. Hypotheses include modest serotonergic and noradrenergic effects, modulation of hypothalamic-pituitary-adrenal-axis cortisol responses, and apigenin's known monoamine oxidase inhibitory activity at higher doses. The clinical effect appears real but modest — chamomile has not been tested as a replacement for selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SNRI) treatment of major depression.

A 2020 analysis looked at the 179 people in the 8-week open-label phase of the later relapse-prevention trial (chamomile extract 1500 mg daily): 100 had GAD without depression and 79 had GAD with comorbid depression. Anxiety relief was similar in both groups. Core depression scores (the six-item core Hamilton depression scale) fell more in those with comorbid depression (p < 0.023), while total depression scores showed only a trend (p = 0.14). The authors called this a preliminary observation and wrote that controlled trials in people with primary major depressive disorder are needed (Amsterdam 2020).

Back to Table of Contents

The Mao 2016 Long-Term Maintenance Trial

Mao and colleagues (2016) published a continuation trial in Phytomedicine examining whether long-term chamomile use prevents GAD symptoms from coming back (relapse). This addresses one of the most important practical questions for any chronic GAD treatment.

Design: 179 outpatients with moderate-to-severe GAD received open-label pharmaceutical-grade chamomile extract, 1500 mg/day (one 500 mg capsule three times daily), for 12 weeks; those who responded were then randomized, double-blind, to either continued chamomile or placebo for 26 additional weeks. The primary outcome was time to relapse.

The authors concluded that long-term chamomile was safe and significantly reduced moderate-to-severe GAD symptoms, but did not significantly reduce the rate of relapse, and that possible chamomile superiority over placebo requires further examination in large-scale studies.

Back to Table of Contents

Chamomile and Sertraline: No Head-to-Head Trial

No published trial has compared chamomile directly with sertraline, the selective serotonin reuptake inhibitor widely used for GAD, or with another selective serotonin reuptake inhibitor. The chamomile trials so far compared chamomile with placebo (Amsterdam 2009, Mao 2016) or gave it open-label (Keefe 2016).

The nearest statement comes from the 2016 open-label study of 179 people with moderate-to-severe GAD: its authors reported that chamomile extract produced a clinically meaningful reduction in GAD symptoms over 8 weeks, “with a response rate comparable to those observed during conventional anxiolytic drug therapy and a favorable adverse event profile,” and wrote that “future comparative effectiveness trials between chamomile and conventional drugs may help determine the optimal risk/benefit of these therapies.” In that study, adverse events occurred in 11.7% of participants, with no serious adverse events, and 15.6% stopped treatment early.

Back to Table of Contents

Chamomile vs Benzodiazepines

In laboratory studies, chamomile's apigenin binds the same molecular target as benzodiazepines (the benzodiazepine site of the gamma-aminobutyric acid-A receptor), at a dramatically weaker affinity; whether this binding explains chamomile's effect in people has not been established. The comparison is informative for understanding what chamomile can and cannot do.

FeatureChamomile (apigenin)Benzodiazepine (alprazolam)
BZD-site affinityLow-micromolar KiLow-nanomolar Ki (~1000× tighter)
Functional classNot established (animal and cell studies conflict)Full agonist
Acute anxiolytic onset30–90 min30–60 min
Acute effect sizeModestLarge
Sedation at anxiolytic doseMinimalSubstantial
Cognitive impairmentMinimalSubstantial
ToleranceNot documentedDevelops within weeks
Physical dependencyNot documentedDevelops with chronic use
Withdrawal syndromeNoneSevere, can include seizures
Respiratory depression riskNone at any reasonable doseSerious with opioid co-use
Fall/fracture risk in elderlyNot documentedSubstantially elevated
Driving impairmentNone at typical dosesDocumented; legal liability

The pattern is clear. Chamomile and benzodiazepines are not interchangeable. Chamomile is for chronic mild-to-moderate anxiety where the trade-off is gentle ongoing relief without disrupting daytime function or creating dependency. Benzodiazepines are for severe acute anxiety or panic where rapid full anxiolysis is needed and short-duration use can be assured.

Patients tapering off chronic benzodiazepine use frequently incorporate chamomile (along with magnesium glycinate, glycine, L-theanine, melatonin, and aggressive cognitive behavioral therapy) as supportive scaffolding during the slow benzodiazepine taper. None of these is a benzodiazepine replacement, but together they take the edge off the withdrawal anxiety and rebound symptoms that make tapers fail.

Back to Table of Contents

Stacking with Other Botanical Anxiolytics

Chamomile is often combined with other gentle botanical anxiolytics. Common stacking:

None of these combinations replace pharmacotherapy in severe GAD or panic disorder. They are useful as primary therapy for mild-to-moderate generalized anxiety, as adjuncts to selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor/cognitive behavioral therapy treatment of more severe anxiety, and as supportive scaffolding during benzodiazepine tapers.

Back to Table of Contents

Preparation, Dose, and Practical Use

For anxiety specifically (as opposed to sleep), the standardized capsule formulation has the strongest evidence base because that is what the trials used. Doses used in the trials and in traditional practice:

Standardized extracts vary considerably in actual apigenin content. The trials used pharmaceutical-grade extracts: 220 mg capsules standardized to 1.2% apigenin (Amsterdam 2009) and 500 mg capsules containing 6 mg of total apigenin-7-glycosides (Mao 2016). Unstandardized over-the-counter (OTC) "chamomile capsule" supplements may have very different apigenin content than the randomized controlled trial (RCT) extracts.

Back to Table of Contents

Cautions

Back to Table of Contents

How Reviews and Guidelines Rate Chamomile for Anxiety

Back to Table of Contents

Key Research Papers

  1. Amsterdam JD et al. (2009). A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology, 29(4):378-382. — PubMed PMID: 19593179
  2. Amsterdam JD et al. (2012). Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans. Alternative Therapies in Health and Medicine, 18(5):44-49. — PubMed PMID: 22894890
  3. Mao JJ et al. (2016). Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine, 23(14):1735-1742. — PubMed PMID: 27912875
  4. Keefe JR et al. (2016). Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder. Phytomedicine, 23(14):1699-1705. — PubMed PMID: 27912871
  5. Viola H et al. (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61(3):213-216. — PubMed PMID: 7617761
  6. Avallone R et al. (2000). Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology, 59(11):1387-1394. — PubMed PMID: 10751547
  7. Salehi B et al. (2019). The therapeutic potential of apigenin. International Journal of Molecular Sciences, 20(6):1305. — PubMed PMID: 30875872
  8. Srivastava JK, Shankar E, Gupta S (2010). Chamomile: A herbal medicine of the past with bright future. Molecular Medicine Reports, 3(6):895-901. — PubMed PMID: 21132119
  9. Hieu TH et al. (2019). Therapeutic efficacy and safety of chamomile for state anxiety, generalized anxiety disorder, insomnia, and sleep quality: A systematic review and meta-analysis. Phytotherapy Research, 33(6):1604-1615. — PubMed PMID: 31006899
  10. Yeung KS et al. (2018). Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance. Phytotherapy Research, 32(5):865-891. — PubMed PMID: 29464801
  11. Amsterdam JD, Li QS, Xie SX, Mao JJ (2020). Putative antidepressant effect of chamomile (Matricaria chamomilla L.) oral extract in subjects with comorbid generalized anxiety disorder and depression. Journal of Alternative and Complementary Medicine, 26(9):813-819. — PubMed PMID: 31808709
  12. Zhang W et al. (2022). Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis. Pharmacological Research, 179:106204. — PubMed PMID: 35378276
  13. Sarris J et al. (2022). Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World Journal of Biological Psychiatry, 23(6):424-455. — PubMed PMID: 35311615
  14. Segal R, Pilote L (2006). Warfarin interaction with Matricaria chamomilla. CMAJ (Canadian Medical Association Journal), 174(9):1281-1282. — PubMed PMID: 16636327

PubMed Topic Searches

  1. PubMed: Chamomile GAD RCTs
  2. PubMed: Apigenin BZD receptor anxiolytic
  3. PubMed: Chamomile and comorbid depression
  4. PubMed: Matricaria placebo-controlled anxiety trials
  5. PubMed: Phytotherapy anxiety systematic reviews
  6. PubMed: Apigenin partial agonist GABA-A

Back to Table of Contents

Connections

Back to Table of Contents